BNP PARIBAS ASSET MANAGEMENT Holding S.A. Has $510.74 Million Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

BNP PARIBAS ASSET MANAGEMENT Holding S.A. trimmed its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 2.9% in the 3rd quarter, HoldingsChannel.com reports. The fund owned 485,847 shares of the biopharmaceutical company’s stock after selling 14,427 shares during the quarter. Regeneron Pharmaceuticals comprises about 1.3% of BNP PARIBAS ASSET MANAGEMENT Holding S.A.’s investment portfolio, making the stock its 9th largest position. BNP PARIBAS ASSET MANAGEMENT Holding S.A.’s holdings in Regeneron Pharmaceuticals were worth $510,741,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also recently modified their holdings of REGN. Brown Lisle Cummings Inc. grew its holdings in Regeneron Pharmaceuticals by 18.2% in the second quarter. Brown Lisle Cummings Inc. now owns 65 shares of the biopharmaceutical company’s stock worth $68,000 after purchasing an additional 10 shares during the period. Sachetta LLC lifted its position in Regeneron Pharmaceuticals by 71.4% during the second quarter. Sachetta LLC now owns 24 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 10 shares during the period. Adirondack Trust Co. lifted its position in Regeneron Pharmaceuticals by 2.4% during the third quarter. Adirondack Trust Co. now owns 431 shares of the biopharmaceutical company’s stock valued at $453,000 after purchasing an additional 10 shares during the period. UMB Bank n.a. lifted its position in Regeneron Pharmaceuticals by 1.1% during the third quarter. UMB Bank n.a. now owns 908 shares of the biopharmaceutical company’s stock valued at $955,000 after purchasing an additional 10 shares during the period. Finally, Western Financial Corp CA raised its position in Regeneron Pharmaceuticals by 0.7% in the second quarter. Western Financial Corp CA now owns 1,819 shares of the biopharmaceutical company’s stock worth $1,912,000 after acquiring an additional 12 shares during the period. 83.31% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

REGN has been the topic of several recent research reports. Evercore ISI decreased their price target on shares of Regeneron Pharmaceuticals from $1,250.00 to $1,175.00 and set an “outperform” rating on the stock in a research report on Thursday, October 24th. Cantor Fitzgerald restated a “neutral” rating and set a $1,015.00 price objective on shares of Regeneron Pharmaceuticals in a research report on Wednesday, October 23rd. Truist Financial decreased their price objective on shares of Regeneron Pharmaceuticals from $1,137.00 to $1,126.00 and set a “buy” rating on the stock in a research report on Friday, November 1st. Royal Bank of Canada decreased their price objective on shares of Regeneron Pharmaceuticals from $1,260.00 to $1,215.00 and set an “outperform” rating on the stock in a research report on Friday, November 1st. Finally, Leerink Partnrs downgraded shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, September 24th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating, eighteen have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, Regeneron Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus price target of $1,099.55.

Insider Transactions at Regeneron Pharmaceuticals

In other news, CFO Christopher R. Fenimore sold 5,680 shares of the business’s stock in a transaction dated Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the sale, the chief financial officer now directly owns 15,305 shares in the company, valued at $18,447,575.65. The trade was a 27.07 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Insiders own 7.48% of the company’s stock.

Regeneron Pharmaceuticals Stock Performance

Regeneron Pharmaceuticals stock opened at $743.35 on Thursday. The company’s 50-day moving average price is $961.76 and its 200-day moving average price is $1,030.14. Regeneron Pharmaceuticals, Inc. has a twelve month low of $736.01 and a twelve month high of $1,211.20. The company has a quick ratio of 4.46, a current ratio of 5.28 and a debt-to-equity ratio of 0.09. The company has a market cap of $81.69 billion, a PE ratio of 18.40, a price-to-earnings-growth ratio of 2.81 and a beta of 0.15.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.